Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria.
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
03
2023
revised:
26
08
2023
accepted:
02
09
2023
medline:
1
11
2023
pubmed:
5
10
2023
entrez:
5
10
2023
Statut:
epublish
Résumé
The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann-Whitney
Identifiants
pubmed: 37795408
doi: 10.1155/2023/8087274
pmc: PMC10547569
doi:
Substances chimiques
Omalizumab
2P471X1Z11
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Neuropeptide Y
0
Substance P
33507-63-0
Anti-Allergic Agents
0
Immunoglobulin E
37341-29-0
Interleukins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8087274Informations de copyright
Copyright © 2023 Cagdas Boyvadoglu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Int J Mol Sci. 2020 Nov 09;21(21):
pubmed: 33182442
J Eur Acad Dermatol Venereol. 2016 Mar;30(3):454-5
pubmed: 25371135
Cell Rep. 2019 Jul 16;28(3):625-639.e6
pubmed: 31315043
J Invest Dermatol. 2014 Nov;134(11):2833-2836
pubmed: 24844859
J Allergy Clin Immunol. 2008 Aug;122(2):421-3
pubmed: 18678344
Int J Dermatol. 2014 Dec;53(12):1526-30
pubmed: 25209952
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2078-2085
pubmed: 31954076
J Invest Dermatol. 2021 Mar;141(3):678-681.e2
pubmed: 32771471
Allergy. 1999 Jan;54(1):46-56
pubmed: 10195357
J Neuroimmunol. 2004 Jan;146(1-2):1-12
pubmed: 14698841
Clin Exp Allergy. 2014 Aug;44(8):1053-60
pubmed: 24902612
J Allergy Clin Immunol. 2013 Jul;132(1):232-5
pubmed: 23260756
Allergy. 2017 Apr;72(4):519-533
pubmed: 27861988
Exp Dermatol. 2010 May;19(5):464-6
pubmed: 20163453
J Dermatolog Treat. 2022 Sep;33(6):2858-2861
pubmed: 35723235
J Allergy Clin Immunol. 2017 Aug;140(2):447-453.e3
pubmed: 28219706
Pediatr Res. 2015 Jan;77(1-1):20-8
pubmed: 25285475
Immunology. 2008 Mar;123(3):398-410
pubmed: 17922833
Allergy Asthma Immunol Res. 2021 May;13(3):498-506
pubmed: 33733642
Eur J Cell Biol. 2012 Jun-Jul;91(6-7):552-66
pubmed: 21982586
Clin Exp Allergy. 2017 Apr;47(4):499-508
pubmed: 28000952
J Allergy Clin Immunol. 2021 Feb;147(2):456-469
pubmed: 33071069